Faisal Khurshid
Stock Analyst at Leerink Partners
(0)
# 4620
Out of 5,240 analysts
14
Total ratings
18.18%
Success rate
-17.67%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Kymera Therapeutics | Maintains: Outperform | 60 60 | 40.09 | 49.66% | 2 | Dec 27, 2024 | |
ANI Pharmaceuticals | Initiates Coverage On: Outperform | 80 | 54.22 | 47.55% | 1 | Dec 11, 2024 | |
Zura Bio | Initiates Coverage On: Outperform | 15 | 1.94 | 673.2% | 1 | Nov 4, 2024 | |
Trevi Therapeutics | Assumes: Outperform | 7 | 3.94 | 77.66% | 1 | Sep 9, 2024 | |
PureTech Health | Assumes: Outperform | 45 | 17.88 | 151.68% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 33 | 11.24 | 193.59% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 5 | 3.65 | 36.99% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 24 | 24 | 0% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 7 | 2.94 | 138.1% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 8 | 6.03 | 32.67% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 5 | 1.01 | 395.05% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 17 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 11 | 4.33 | 154.04% | 1 | Mar 21, 2023 |